Literature DB >> 12706247

Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression.

Oskar Hansson1, Jesper Nylandsted, Roger F Castilho, Marcel Leist, Marja Jäättelä, Patrik Brundin.   

Abstract

Huntington's disease (HD) is a neurodegenerative disorder caused by expansion of a polyglutamine tract in a protein called huntingtin. The inducible form of heat shock protein 70 (Hsp70) has been shown to reduce polyglutamine-induced toxicity. To investigate if overexpression of Hsp70 can affect disease progression in a mouse model of HD, we crossed R6/2 mice, expressing exon 1 of the HD gene with an expanded CAG repeat, with mice overexpressing Hsp70 (both types of transgenic mice were of the CBAxC57BL/6 strain). The resulting R6/2-Hsp70 transgenics exhibited 5- to 15-fold increases in Hsp70 expression in neocortical, hippocampal and basal ganglia regions. This correlated with a delayed loss of body weight compared to R6/2 mice. However, the number or size of nuclear inclusions, the loss of brain weight, reduction of striatal volume, reduction in size of striatal projection neurons, downregulation of DARPP-32, development of paw clasping phenotype and early death of the mice were not affected by Hsp70 overexpression. Interestingly, the polyglutamine protein affected the potential rescuing agent, because in older R6/2-Hsp70 mice a large proportion of the Hsp70 protein was sequestrated in nuclear inclusions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12706247     DOI: 10.1016/s0006-8993(02)04275-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  40 in total

1.  hsp72, a host determinant of measles virus neurovirulence.

Authors:  Thomas Carsillo; Zachary Traylor; Changsun Choi; Stefan Niewiesk; Michael Oglesbee
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 2.  Heat shock protein 70 (hsp70) as an emerging drug target.

Authors:  Christopher G Evans; Lyra Chang; Jason E Gestwicki
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

Review 3.  Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases.

Authors:  Amanda K Davis; William B Pratt; Andrew P Lieberman; Yoichi Osawa
Journal:  Cell Mol Life Sci       Date:  2019-09-24       Impact factor: 9.261

Review 4.  Opportunities and challenges for molecular chaperone modulation to treat protein-conformational brain diseases.

Authors:  Herman van der Putten; Gregor P Lotz
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

5.  cAMP-response element-binding protein and heat-shock protein 70 additively suppress polyglutamine-mediated toxicity in Drosophila.

Authors:  Kanae Iijima-Ando; Priscilla Wu; Eric A Drier; Koichi Iijima; Jerry C P Yin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-11       Impact factor: 11.205

Review 6.  Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.

Authors:  Sara D Reis; Brígida R Pinho; Jorge M A Oliveira
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

7.  Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease.

Authors:  Jennifer L Wacker; Shao-Yi Huang; Andrew D Steele; Rebecca Aron; Gregor P Lotz; QuangVu Nguyen; Flaviano Giorgini; Erik D Roberson; Susan Lindquist; Eliezer Masliah; Paul J Muchowski
Journal:  J Neurosci       Date:  2009-07-15       Impact factor: 6.167

8.  The HSP70 molecular chaperone is not beneficial in a mouse model of alpha-synucleinopathy.

Authors:  Derya R Shimshek; Matthias Mueller; Christoph Wiessner; Tatjana Schweizer; P Herman van der Putten
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

9.  Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.

Authors:  Carmela Giampà; Daunia Laurenti; Serenella Anzilotti; Giorgio Bernardi; Frank S Menniti; Francesca Romana Fusco
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

10.  Protective effect of geranylgeranylacetone via enhancement of HSPB8 induction in desmin-related cardiomyopathy.

Authors:  Atsushi Sanbe; Takuya Daicho; Reiko Mizutani; Toshiya Endo; Noriko Miyauchi; Junji Yamauchi; Kouichi Tanonaka; Charles Glabe; Akito Tanoue
Journal:  PLoS One       Date:  2009-04-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.